{
    "nctId": "NCT00246597",
    "briefTitle": "A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer",
    "officialTitle": "A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "Anemia, Breast Neoplasms, Hemoglobins, Quality of Life, Chemotherapy, Adjuvant",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 37,
    "primaryOutcomeMeasure": "To assess the effect of PROCRIT\u00ae on impairment of cognitive and executive function",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologic diagnosis of Stage I, II or III cancer (chemotherapy na\u00efve for breast cancer) with anthracycline-based adjuvant chemotherapy with or without a taxane\n* Hemoglobin \\>=9 and \\<=14 g/dL unrelated to transfusion\n* Able to read, understand and complete QoL \\& Cognition tools\n* Patients with reproductive potential must have a negative serum pregnancy test within 7 days of study enrollment and use an adequate contraceptive method\n\nExclusion Criteria:\n\n* Patients who will receive more than a total of 24 weeks of chemotherapy\n* psychiatric or neurologic condition that would prevent informed consent and completion of questionnaires or that is poorly controlled with the current treatment regimen\n* severe hemiparesis or other condition, distal neuropathy, action tremor or other motor dysfunction, visual deficiencies preventing/decrease bimanual keyboard operation\n* severe bradyphrenia (slow thinking) or bradykinesia (slow movement)",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}